|
POLR2B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.27710000019654E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.93419999999978E-06 |
| Normal-vs-Stage2 |
2.640100E-04 |
| Normal-vs-Stage3 |
3.35500000003819E-07 |
| Normal-vs-Stage4 |
1.16449999643109E-08 |
| Stage1-vs-Stage2 |
6.679000E-01 |
| Stage1-vs-Stage3 |
1.203200E-01 |
| Stage1-vs-Stage4 |
2.791800E-02 |
| Stage2-vs-Stage3 |
5.329800E-01 |
| Stage2-vs-Stage4 |
1.794970E-01 |
| Stage3-vs-Stage4 |
3.322000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.79969999592711E-08 |
| Normal-vs-AfricanAmerican |
1.989640E-02 |
| Normal-vs-Asian |
1.351660E-04 |
| Caucasian-vs-AfricanAmerican |
2.652200E-01 |
| Caucasian-vs-Asian |
8.325000E-01 |
| AfricanAmerican-vs-Asian |
4.145000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.75149999953805E-08 |
| Normal-vs-Female |
1.08949999999552E-06 |
| Male-vs-Female |
2.333200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.21520000000175E-05 |
| Normal-vs-Age(41-60Yrs) |
1.09260000002998E-06 |
| Normal-vs-Age(61-80Yrs) |
6.84629997138586E-09 |
| Normal-vs-Age(81-100Yrs) |
3.996200E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.477400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.566000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.006000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.658400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.097200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.811600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.846000E-02 |
| Classical-VS-Follicular |
1.923920E-02 |
| Classical-VS-Other |
1.548400E-01 |
| Classical-VS-Normal |
1.97337999999769E-05 |
| Tall-VS-Follicular |
7.097400E-01 |
| Tall-VS-Other |
6.724000E-01 |
| Tall-VS-Normal |
2.67720000002303E-06 |
| Follicular-VS-Other |
6.047600E-01 |
| Follicular-VS-Normal |
1.14979999998877E-06 |
| Other-VS-Normal |
2.597100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.38240000014234E-07 |
| Normal-vs-N1 |
9.10090000028063E-08 |
| N0-vs-N1 |
1.734840E-01 |
|
|
